# Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Study · id `cardio:ct-nct02164864` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02164864](<https://clinicaltrials.gov/study/NCT02164864>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02164864

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2725 participants.

## Technical summary

Registry record NCT02164864. Randomized; no masking; primary purpose treatment. Start 2014-07-22 (actual); primary completion 2017-06-05 (actual). Results posted on 2018-07-31.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2725 participants (enrolled count; ClinicalTrials.gov record NCT02164864, source copy `cardio:ctgov-nct02164864-2018-07-31`, retrieved 2026-10-26)
- Started: 2014-07-22 (actual) (ClinicalTrials.gov record NCT02164864, source copy `cardio:ctgov-nct02164864-2018-07-31`, retrieved 2026-10-26)
- Primary completion: 2017-06-05 (actual) (ClinicalTrials.gov record NCT02164864, source copy `cardio:ctgov-nct02164864-2018-07-31`, retrieved 2026-10-26)
- Completion: 2017-06-05 (actual) (ClinicalTrials.gov record NCT02164864, source copy `cardio:ctgov-nct02164864-2018-07-31`, retrieved 2026-10-26)
- Results first posted: 2018-07-31 (ClinicalTrials.gov record NCT02164864, source copy `cardio:ctgov-nct02164864-2018-07-31`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Croatia; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong SAR China; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Poland; Portugal; Russia; Singapore; Slovakia; Slovenia; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT02164864, source copy `cardio:ctgov-nct02164864-2018-07-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02164864-2018-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
- Condition: Atrial Fibrillation
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): Dabigatran Etexilate 110mg
- Intervention (Drug): Warfarin 3mg
- Intervention (Drug): Aspirin
- Intervention (Drug): Dabigatran Etexilate 150mg
- Intervention (Drug): Clopidogrel or Ticagrelor
- Intervention (Drug): Clopidogrel or Ticagrelor
- Intervention (Drug): Warfarin 5mg
- Intervention (Drug): Clopidogrel or Ticagrelor
- Intervention (Drug): Warfarin 1mg
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (`cardio:pubmed-28844193`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI (`cardio:pubmed-31439336`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial (`cardio:pubmed-32252548`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI (`cardio:pubmed-32389658`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 869c9a59323717f85b97ceed7d76a8e949212b255484361d124ff5b44b14daa8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
